Tag Archive for: Anglo Nordic

Weekly roundup: Awards, events, financings and 2 new episodes of Optimum TV

/in

R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease R1 Therapeutics, Inc, a clinical-stage biopharmaceutical company focused on the development of first-in-class therapies for patients with kidney disease, announced its launch with an oversubscribed $77.5 million Series A financing, along with the […]

Read more

Optimum’s top take-aways from Anglonordic 2025

/in

If a good rule of thumb for a conference is how full the hall is at the end of the day compared to the start, then the 21st Anglonordic Life Science Conference held last Thursday, attended by well over 300 people, was a resounding success.  Maybe it was still full because attendees were keen to […]

Read more

How Early-stage VCs are Adjusting in a Bear Market

/in

As part of a panel session, hosted by Stephen Hansen, at the Anglonordic Life Science conference on 5 May, Optimum’s clients explored the latest dynamics of syndicate building for early-stage VCs.

Read more